
Natera, Inc.
NTRANASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$331.62
+US$7.19 · +2.21%
NTRA公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Hold
Wait — insufficient conviction to act
估值
65
Undervalued
动量
69
Gaining
情绪
47
Mixed
风险韧性
57
Elevated Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
- 行业
- Medical - Diagnostics & Research
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- Steven Leonard Chapman
- 上市以来
- 2015年7月1日
- 雇员
- 6,138
市场位置
- 成交量
- 121.51万
- 0.82× 平均值
- 平均成交量
- 147.97万
- 日均成交量
- 市值
- 475.52亿 USD
- 贝塔
- 1.51
- 市场参考 1
财报历史与展望
- 最新财年每股收益
- -1.52
- 2025财年
- 最新财年收入
- 23.06亿 USD
- 2025财年 · 同比+35.90%
年度每股收益趋势
已公布业绩及可用的市场共识预期。
年度营收趋势
已公布业绩及可用的市场共识预期。
NTRA同业公司
继续GoAI的研究
在 GoAI 中研究NTRAresearch.disclaimer





